Simplify Logo
Intuitive Surgical

Intuitive Surgical

Manufactures robotic surgical systems and services

Product Manager - Diagnostics, Global Services

Full-Time
$125.5k - $212.4k/yr

+ Incentives + Equity

Mid, Senior
Bachelor's, Master's, PhD
Sunnyvale, CA, USA
In Person

Travel up to 25% required.

About the job

Requirements
  • A minimum of 5 years of related experience with a Bachelor's degree, or 3 years of experience with a Master's degree, or a PhD without experience, or equivalent work experience.
  • Technical experience with medical device diagnostics or an equivalent area.
  • Technical knowledge of Intuitive products.
  • Experience with product management, continuous improvement initiatives, Lean/Six Sigma, or an equivalent discipline.
  • Experience building business cases using qualitative and quantitative data to secure funding, resources, or project or program support.
  • Experience investigating and defining complex problems before solution development.
  • Experience with market research, voice of customer feedback, voice of service feedback, or equivalent.
  • Formal or informal leadership of cross-functional teams to implement or launch key initiatives.
  • Critical thinking, attention to detail, and data-driven decision making.
  • Ability to develop and present impactful presentations for cross-functional audiences, director- or vice president-level leadership, and global stakeholders.
  • Ability to build relationships and partner closely with key stakeholders.
  • Strong written and verbal communication skills.
  • Ability to prioritize and manage multiple initiatives and deadlines.
  • Self-direction and the ability to proactively seek advice when needed.
  • Strong knowledge of the Microsoft Office product suite.
  • Ability to travel 25%.
Responsibilities
  • Operate as the product manager for diagnostic service technology to ensure service professionals have the resources and tools required to diagnose technical issues with Intuitive devices effectively and efficiently.
  • Maintain deep technical expertise regarding current methods for diagnosing technical product issues to identify pain points, inefficiencies, and opportunities to evolve diagnosis processes.
  • Challenge current and historical methods for diagnosing technical product issues remotely and on premise.
  • Explore new approaches for diagnosing technical issues to streamline and accelerate diagnosis, improve service professional proficiency, drive efficiency and scalability, and protect Intuitive intellectual property.
  • Develop a long-term strategic vision for diagnostic capabilities and medium-term and short-term roadmaps supporting that vision.
  • Partner with Product Managers responsible for on-premises and remote service technology platforms to identify diagnostic innovations within those platforms.
  • Partner with product development teams, software engineers, and system analysts to scope diagnostic innovation requirements throughout the product pipeline and ensure consistent deployment across the product portfolio.
  • Partner with Services Product Managers, Product Performance Engineers, Product Support Engineers, Technical Support Engineers, and Digital Customer Support to define and deploy new diagnostic capabilities through existing and emerging service technology.
  • Use knowledge of service professional and customer needs and market intelligence to outline challenges and opportunities and inform solution definition.
  • Partner with software engineering, interaction design engineering, human factors engineering, and other internal partners to drive effective solution design decisions.
  • Develop business cases for new features, capabilities, and service technology; demonstrate the desirability, viability, feasibility, and return on investment of proposed solutions; and secure stakeholder and leadership support and funding.
  • Develop and track goals and objectives for diagnostic capabilities and service technologies, aligned with business unit goals and corporate objectives.
  • Serve as a diagnostic subject matter expert for Service Leadership, product business units, training, and marketing teams.
  • Provide subject matter expertise and strategic input to evaluate and prioritize new service technologies and capabilities.
  • Attend conferences, customer visits, job shadowing, and other relevant activities to build and maintain subject matter expertise and familiarity with Global Services, customer needs, and strategic opportunities.

About the company

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, with 468 da Vinci placements.
  • Intuitive opened a 316,000-square-foot Penang plant, creating 1,200 jobs by 2032.
  • Direct Italy-Spain-Portugal distribution expanded March 2, 2026, strengthening European control.

What critics are saying

  • FDA logged a February 18, 2026 class-2 recall for da Vinci 5 software crashes.
  • Johnson & Johnson's Ottava won FDA approval in summer 2026, attacking Intuitive's core.
  • Medtronic Hugo and J&J Ottava commoditize robotics, breaking da Vinci's moat by 2028.

What makes Intuitive Surgical unique

  • da Vinci 5 won FDA cardiac clearance on January 26, 2026.
  • Ion and da Vinci generate recurring instruments, accessories, and service revenue.
  • da Vinci SP earned CE mark expansion on September 15, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.